Journal
ONCOTARGET
Volume 7, Issue 22, Pages 33237-33245Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.8909
Keywords
angiogenesis; inflammation; thalidomide; cancer; teratogenesis
Categories
Funding
- Wellcome Trust-NIH [098252/Z/12/Z]
- Intramural Research Program, NCI, NIH
- Intramural Research Program, NIA, NIH
- Wellcome Trust [098252/Z/12/Z] Funding Source: Wellcome Trust
Ask authors/readers for more resources
Thalidomide, a drug known for its teratogenic side-effects, is used successfully to treat a variety of clinical conditions including leprosy and multiple myeloma. Intense efforts are underway to synthesize and identify safer, clinically relevant analogs. Here, we conduct a preliminary in vivo screen of a library of new thalidomide analogs to determine which agents demonstrate activity, and describe a cohort of compounds with anti-angiogenic properties, anti-inflammatory properties and some compounds which exhibited both. The combination of the in vivo zebrafish and chicken embryo model systems allows for the accelerated discovery of new, potential therapies for cancerous and inflammatory conditions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available